Seagen Investor Relations Material
Latest events
Q4 2022
Seagen
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Seagen Inc
Access all reports
Segment Data
Access more data
Revenue by
Source
Net product sales
Royalty revenues
Collaboration and license agreement revenues
Expenses by
Financials
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer. The company markets LONZA (vinorelbine tartrate) injection, which is used to treat various types of cancer. It also focuses on the development of Seaglass (poly-L-glutamic acid), a compound that is undergoing clinical study for the treatment of chemotherapy-induced nausea and vomiting (CINV). The company was formerly known as Ocean Pharmaceuticals, Inc. and changed its name to Seagen Inc. in August 1995. Seagen Inc. is based in Bothell, Washington.
Latest articles
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States